CSIMarket
 
Enanta Pharmaceuticals Inc  (ENTA)
Other Ticker:  
 
 
Price: $14.2100 $0.35 2.525%
Day's High: $14.37 Week Perf: -5.77 %
Day's Low: $ 13.71 30 Day Perf: 7.57 %
Volume (M): 197 52 Wk High: $ 43.06
Volume (M$): $ 2,792 52 Wk Avg: $18.01
Open: $13.80 52 Wk Low: $8.08



 Market Capitalization (Millions $) 298
 Shares Outstanding (Millions) 21
 Employees 112
 Revenues (TTM) (Millions $) 79
 Net Income (TTM) (Millions $) -134
 Cash Flow (TTM) (Millions $) 41
 Capital Exp. (TTM) (Millions $) 9

Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals Inc is a biotechnology company that specializes in developing small molecule drugs for infectious diseases, liver diseases, and cancer. The company was founded in 1995 and is located in Watertown, Massachusetts.

Enantaes main focus is on developing antiviral drugs for the treatment of hepatitis C virus (HCV) and respiratory syncytial virus (RSV). The companyes lead product, paritaprevir, is a protease inhibitor used in combination with other drugs to treat patients with chronic HCV infection. Paritaprevir is sold under the brand name VIEKIRA PAK by AbbVie Inc.

In addition to paritaprevir, Enanta has several other drugs in its pipeline for the treatment of HCV, such as EDP-514, a non-nucleoside polymerase inhibitor, and EDP-305, a farnesoid X receptor agonist.

Aside from HCV, Enanta is also developing drugs for RSV, a virus that causes respiratory infections in infants and older adults. The companyes lead RSV asset, EDP-938, is an orally bioavailable fusion inhibitor that is designed to prevent the virus from entering human cells. Enanta is currently conducting Phase 2a clinical trials on EDP-938.

Aside from its antiviral programs, Enanta is also developing drugs for the treatment of non-alcoholic steatohepatitis (NASH), a liver disease that is closely associated with obesity and diabetes. Enantaes lead NASH asset, EDP-305, is a farnesoid X receptor agonist that is designed to reduce liver inflammation and fibrosis. Enanta is currently conducting a Phase 2a clinical trial on EDP-30

Enanta has established collaborations with several major pharmaceutical companies, including AbbVie, Novartis, and Gilead Sciences. These collaborations provide the company with funding and expertise to advance its drug development programs.

Enanta Pharmaceuticals Inc has received numerous awards and recognitions for its drug development efforts, including the 2015 Technology of the Year Award by the Massachusetts Technology Leadership Council and the 2016 Biotech Pioneer Award by the Boston Business Journal.


   Company Address: 500 Arsenal Street Watertown 2472 MA
   Company Phone Number: 607-0800   Stock Exchange / Ticker: NASDAQ ENTA
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc Overcomes Revenue Setback, Prepares for Resurgence in Q4 2023

Enanta Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections, recently announced its financial results for the July to September 30, 2023, period. During this period, the company reported an increase in losses, which expanded from $1.27 per share a year prior to $1.32 per share. However, it is worth noting that the earnings per share (EPS) improved from -$1.86 in the preceding reporting period.
The revenue for the same period decreased by 6.817% to $18.93 million compared to $20.32 million in the previous reporting period. While sequentially, the revenue advanced slightly by 0.212% from $18.89 million. This decline in revenue could raise concerns, as it may indicate slowing demand for Enanta Pharmaceuticals Inc's products.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc Faces Losses and Decline in Revenue, While Major Pharmaceutical Preparations Sector Thrives



Enanta Pharmaceuticals Inc, a leading company in the Major Pharmaceutical Preparations sector, reported a decline in revenue for the most recent fiscal period, resulting in losses. The company's revenue fell by -3.014% to $18.89 million, with a shortfall per share of $-1.86. This figure contrasts with the previous year's quarter, which saw a shortfall per share of $-1.53.
The rest of the Major Pharmaceutical Preparations sector, however, recorded a substantial rise in their top-line revenues in the third quarter of 2023. Looking at Enanta Pharmaceuticals' results from the previous quarter, revenue increased by 6.165% from $17.80 million, accompanied by an advanced shortfall from $-1.79 per share.
Unfortunately, Enanta Pharmaceuticals Inc realized a higher net shortfall of $-39.065 million for the most recent fiscal period, compared to $-31.700 million a year ago. Despite this disappointing performance, there seems to be some progress, as the value of accounts receivable has shown improvement compared to the previous year.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc faces alarming revenue drop and deficit in Q2 2023 earnings

Investing in the stock market can be both exciting and risky, and it's important to remain cautious when making investment decisions. Recent reports released by Enanta Pharmaceuticals Inc have indicated that their revenue has decreased significantly, leading to a deficit in the second quarter of 2023. The revenue decreased to $17.80 million, a drop of 4.921%, and the shortfall per share was reported at $-1.79, up from $-1.63 per share in the previous financial reporting period.
This is an alarming situation for investors and shareholders, as it shows a decrease in the company's performance from the previous year's financial results. The company's revenue fell by 24.55% from $23.59 million, and the shortfall per share increased from $-1.39 per share reported in the previous year. Moreover, during the second quarter of 2023, Enanta Pharmaceuticals Inc realized a net shortfall of $-37.658 million, which is larger than the $-33.592 million reported a year ago.






 

Enanta Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com